title: Specific treatment for cancer-associated thrombosis.
abstract: Mike Laffan speaks to Gemma Westcott, Commissioning Editor: Michael Laffan is Professor of Haemostasis and Thrombosis in the Department of Haematology at Imperial College, London, UK, and Director of the Hammersmith Hospital Haemophilia Centre. He trained in medicine at Oxford University and hematology at the Hammersmith and Royal Free hospitals in London. His principal research interests are the structure-function relationship of von Willebrand factor, in particular the role of glycosylation, and the mechanisms and regulation of thrombin generation. He has published extensively on hemostasis and recently edited the 11th edition of Practical Haematology. He also served on NEQAS and the British Committee for Standards in Haematology Task force on Haemostasis and Thrombosis.
authors.affiliation: Department of Haematology, Imperial College London, London, SW7 2AZ, UK.|Department of Haematology, Imperial College Healthcare Trust, Greater London, W2 1NY, UK.
authors.forename: Mike
authors.initials: M
authors.lastname: Laffan
authors.forename: Gemma
authors.initials: G
authors.lastname: Westcott
mesh_terms: D019468:Disease Management; D006801:Humans; D009369:Neoplasms / Q000150:complications*; D010348:Patient Care Team; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013923:Thromboembolism / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D013927:Thrombosis / Q000175:diagnosis / Q000209:etiology* / Q000517:prevention & control / Q000628:therapy*; D016896:Treatment Outcome
keywords: anticoagulation; cancer; heparin; low-molecular-weight heparin; thrombosis